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Patients infected with COVID-19 are at higher risk of thrombosis, suggesting an 
important role of COVID-19 induced coagulopathy. Abnormal coagulation param-
eters such as elevation in D-dimer are found in patients, with frequent thrombotic 
events ranging from peripheral ischemia, pulmonary thromboembolism to dissemi-
nated intravascular coagulation. Recently, the role of antiphospholipid antibodies 
(aPL) in the pathophysiology of COVID-19 have been questioned but it remains 
unclear whether they contribute to coagulopathy. We aim to evaluate the presence 
of aPL, including LAC, aCL (IgG, IgM), aβ2GPI (IgG, IgM) in a cohort of patients 
with SARS-CoV-2, study clinical associations and discuss the relevance. The 
relevance of aPLs in patients with COVID-19 is yet to be determined. Inflammation 
is closely associated to thrombosis and the presence of inflammatory mediators 
in COVID-19 infection can lead to thrombosis. Further studies are needed before 
to determine the role of aPL in COVID-19 patients and their relationship with 
thrombosis. The presence of aPL should be carefully interpreted as it is important to 
evaluate the persistence of aPL positivity in patients infected with COVID-19.
Keywords: antiphospholipid antibodies, covid-19, thrombotic, cardiolipin, lupus 
anticoagulant
1. Introduction
COVID-19 has swept through the world in the last 6 months with 28,584,158 
confirmed cases, including 916,955 deaths, being reported to the World Health 
Organization (WHO), on September 13th 2020 [1].
COVID-19 is caused by SARS-CoV2-virus, a member of coronaviridae that 
includes MERS-CoV2 which is responsible for severe respiratory illness and causes 
acute respiratory distress syndrome [2]. Many patients infected with COVID-19 
develop a hyperinflammatory response due to cytokine storm syndrome which 
associates with high mortality [3]. Recent studies demonstrated an association 
between COVID-19 severity and inflammatory biomarkers such as C-reactive 
protein, procalcitonin, IL-6 and ferritin. In addition, a high incidence of thrombotic 
events suggests an important role of COVID-19-induced coagulopathy, despite 
the use of prophylactic doses of low molecular weight heparin [4]. Advanced age 
and comorbidities are predictors of increased mortality in COVID-19, which may 
facilitate thrombosis in these individuals [5].
Several hemostasis laboratory parameters are altered in patients with COVID-
19 which constitutes an argument in favor of coagulopathy [6–10]. Abnormal 
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coagulation parameters such as prolonged aPTT coagulation times, D-dimer eleva-
tion and fibrinogen degradation products correlate with COVID-19 severity and are 
risk factors for higher mortality [10–12].
There are increasing cases of thrombotic events ranging from venous throm-
boembolic disease, pulmonary thromboembolism to disseminated intravascular 
coagulation, as well as reports of arterial thrombosis including strokes and myocar-
dial infarctions [13–15]. The activation of leukocytes, endothelium and plaquettes 
due to cytokine storm, as well as hypoxic vaso-occlusion and direct activation of 
cells by viral transduction are several mechanisms by which COVID-19 infection 
may lead to thrombosis [16].
Recently studies have been published about the role of antiphospholipid anti-
bodies (aPL) in SARSCoV-2 patients, leading investigators to start measuring aPL in 
these patients because of the hypercoagulable state [17–21].
Antiphospholipid syndrome is an autoimmune condition that leads to 
autoantibodies creation. These autoantibodies react against phospholipids and 
phospholipid-binding proteins such as beta-2-glycoprotein I (β2GPI) and activate 
endothelial cells, platelets, and neutrophils, leading to thrombosis [22, 23]. The 
ability to promote thrombosis in arterial and venous circuits is a defining character-
istic of antiphospholipid syndrome. The catastrophic variant of antiphospholipid 
syndrome is sometimes fatal and resembles to diffuse coagulopathy seen in patients 
with COVID-19 [24]. Classification criteria for APS includes lupus anticoagulant 
(LAC), anticardiolipin (aCL) and antibeta2-glycoprotein I antibodies (aβ2GPI) IgG 
or IgM, if persistently present [25].
The theory involving aPL in COVID-19 infected patients is intriguing however, 
most studies published so far only include one point of measurement, usually dur-
ing the acute phase, without confirmation after at least three months, as defined in 
laboratory criteria of antiphospholipid syndrome [26].
Lupus anticoagulant (LA) is a well-known case of aPTT prolongation, which 
can be detected in a significant percentage of COVID-19 infected patients. Several 
biological causes such as high fibrinogen, factor VIII levels and biomarkers such as 
elevated C-reactive protein (CRP) and the presence of antiphospholipid antibodies 
may affect the aPTT [27].
We should also keep in mind that aPL can arise transiently in patients with criti-
cal illness and various infections [28]. The presence of these antibodies can lead to 
thrombotic events, making it difficult to differentiate from other types of throm-
bosis. Viral infections, such as VIH, hepatitis C and parvovirus B19 are triggers of 
transient aPL, due to a mechanism of molecular mimicry mechanism [29].
To investigate the role of aPL in COVID-19, it is important to evaluate all criteria 
of aPL, including LAC, aCL and aβ2GPI antibodies with their isotype and to obtain 
confirmation after at least 3 months, in concordance with the laboratory crite-
ria of APS.
In this report, we illustrate the presence of aPL, including LAC, aCL (IgG, IgM) 
and aβ2GPI (IgG, IgM) in a cohort of patients with SARS-CoV-2 and discuss the 
relevance.
2. Materials and methods
We performed a single-centre, cross-sectional study between March 15th and 
September 15th 2020. The data from all patients who had tested positive for COVID-
19 and had presented with thromboembolic complications were collected in a 
prospectively maintained database and compared to the data from patients without 
thromboembolic complications. Inclusion criteria: (a) aged >18 years old; (b) no 
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previous diagnosis of APS (c) positive for COVID-19 (d) patients that required hos-
pitalization. Registry data included the following co-variables: (1) sociodemographic 
baseline characteristics, such as sex and age; (2) baseline comorbidities including 
hypertension, dyslipidaemia, hyperuricemia, diabetes mellitus, heart disease, lung 
disease; (3) need for anticoagulation prior to hospitalization (4) thromboembolic 
complications during admission (5) mean time of hospitalization (days) (6) labora-
torial work (7) aPL positity and isotype determination during hospitalization and 
confirmed after a 3 month period.
2.1 COVID-19 detection
The diagnosis of SARS-CoV-2 infection was confirmed in all the patients by 
reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay or serologic 
testing.
2.2 Analytical parameters
Screening blood tests included hemogram, D-dimer, C-reactive protein (CRP), 
procalcitonin, transaminases (serum alanine aminotransferase, serum aspartate 
aminotransferase), serum lactate dehydrogenase, ferritin, fibrinogen, coagulation 
times (PTT and aPTT).
2.3 Thrombosis diagnosis
Computerized tomography was performed to identify COVID-19-
thromboembolic related complications. Duplex ultrasound was systematically 
performed to diagnose proximal and distal lower extremity deep vein thrombosis. 
Thoracic computer-tomography/angiography was performed if pulmonary embo-
lism was suspected and brain computer-tomography in the case of stroke.
All patients received prophylactic or therapeutic dose low molecular weight 
heparin (LMWH) (enoxaparin) or unfractionated heparin (UFH), accordingly to 
thrombotic risk evaluated at admission.
2.4 Detection of aPL
Determination Serum aCL and aβ2GP1 (IgG, IgM) were determined by the 
chemiluminescence assay (CIA) (INOVA) and IgG/IgM aPS/PT were determined by 
ELISA (INOVA).
The detection of LA in human citrated plasma was performed by the HemosIL 
dRVVT Screen and HemosIL dRVVT confirm assays, as recommended by the 
International Society on Thrombosis and Hemostasis (ISTH).
aPL positivity was determined at admission and confirmed after 3 months.
2.5 Statistical analysis
Mann–Whitney U test, χ2 test, or Fisher’s exact test were utilized to compare 
differences between group A (with thromboembolic complications) and group 
B (without thromboembolic complications). A two-sided α of less than 0.05 was 
considered statistically significant. Statistical analyses were performed on SPSS 
20.0 package (SPSS Inc.).
Patient dRVVT screen (low phospholipid concentration) and confirm 
(high phospholipid concentration) results were normalized. Cut-off value was 
1.20 for both screen ratio and screen ratio/confirm ratio, demonstrating the 
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phospholipo-dependence; Anticardiolipin IgG/IgM and/or anti-β2-glycoprotein-I 
IgG antibodies was defined as elevated if the titer was >20 CU (99th percentile).
3. Results
Median age in the patient population was 63.2 (range 36-83) years, with a female 
predominance (66%). The median stay at the hospital was 9 (range 2-19) days. 
Sociodemographic baseline characteristics, medical history, and comorbidities, as 
well as thrombotic complications are shown in Table 1.
On admission, they received prophylactic (45%) or therapeutic (55%) dose low 
molecular heparin. None had received any anticoagulant drug nor had thromboem-
bolic events prior to admission. Thrombotic events were reported in 18 patients and 
included 7 pulmonary embolisms, 1 aortic thrombosis, 1 brachial vein thrombosis, 1 
stroke, 1 heart attack, and 7 deep vein thrombosis.
Patients with thrombosis were older (64.8 (IQR 36-83) vs. 60.4 (43-79), p 0.04), 
more likely to have diabetes (9(50%) vs. 2 (12.5%), p 0.03), dyslipidaemia (12 
(66%) vs. 5 (36%), p 0.04) and higher levels of D-dimer (3797 (IQR 671-6407) vs. 
480 (362-944), p 0.03), serum lactate dehydrogenase (451.3 (IQR 286.3-637.5) vs. 
277.7 (205.8-317.5), p 0.02) and a higher mean hospitalization time (9 (6-11) vs. 5.7 
(2.5-9.5), p 0.04).
Overall, 6 out of 18 patients with thrombotic complications were negative for 
all criteria aPL (LAC, aCL and aβ2GPI IgG and IgM), 10 patients had at least one 
aPL positive, 8 of which were LAC positive. 2 out of 8 positive LAC patients were 
positive but that this is not a false positive result since CRP was elevated up to 
20-40 mg/L and routine aPTT was more prolonged then expected according to the 
CRP level and aCL IgG was positive. Two patients with negative for LAC were single 
positive for aCL IgG. 2 patients out of the 16 patients without thrombotic complica-
tions was positive for LAC, and aCL and 1 was positive for LAC alone.
Repeat positive aPL results three months after the first occasion could be per-
formed in all patients except for 3, since two patients died from thrombotic com-
plications associated with COVID-19 and the other patient could not be reached. 
aPL was repeated in 13 patients that were positive during the first period of testing. 
6 out of 13 patients were LAC negative on the second occasion. Out of the 10 with 
positive aPL and thrombotic complications during the first period of testing, 1 was 
triple positive for LAC, aCL and aβ2GPI and another was positive for LAC and aCL. 
As for patients without thrombotic complications, one patient was positive for LAC 
and aCL and another was positive for LAC alone.
The group with thrombotic complications had a higher aTPP time than the 
group without thrombotic complications however, the difference between the two 
was not significative. Patients with positive LAC had a more prolonged aTPP time 
than those with negative LAC. 5 out of 8 patients with thrombotic complications 
that had positive LAC had a mean aTPP of 46.2 s. Out of the 5, 3 had positive LAC 
after 3 months.
When exploring the effect of hyperinflammation and thrombosis, we found 
that C-reactive protein (CRP) levels significantly associated with D-dimer levels 
(p 0.004) and aPL elevation (p 0.02) in the group with thrombotic events during 
the first testing period however, no association was found between CPR and aPL 
(p 0.5) and D-dimer elevation (0.8) during the second testing period.
We found no differences between both groups in aPL positivity, aTTP and TP 
times (s), fibrinogen, lymphocytes, C-reactive protein, serum creatine, serum 
ferritin and procalcitonin.
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OR (Cl 95%) P value
Male 7 (39%) 9 (64%) 0.35 (0.08-1.50) 0.16
Age (years) 64.8 (IQR 36-83) 60.4 (43-79) — 0.04
Smokers (%) 10 (55%) 4 (25%) 3.75 (0.89-16.2) 0.08
Hypertension (%) 9 (50%) 7 (43%) 1.28 (0.33-4.97) 0.74
Diabetes (%) 9 (50%) 2 (12.5%) 7 (1.22-40.1) 0.03
Dyslipidaemia (%) 12 (66%) 5 (36%) 4.4 (1.05-18.6) 0.04
Hyperuricemia (%) 2 (11%) 1 (0.06%) 1.85 (0.15-22.9) 0.62
Cardiovascular  
disease (%)
3 (17%) 2 (12.5%) 1.2 (0.17-8.4) 0.85
Pulmonary disease (%) 2 (11%) 0 (0%) 5 (0.22-112.3) 0.31
Coagulation tests
Prothrombin time (s)
13.5 (12-34) 12.6 (10.8-13.4) — 0.47
Activated partial 
thromboplastin time (s)
36.3 (30.2-46.7) 33.5 (31.3-36.7) — 0.86
Fibrinogen (g/L) 536 (393-947) 556 (569-962) — 0.31




8 (44%) 3 (19%) 3.47 (0.72-16.5) 0.12
Elevated cardiolipin 
(IgG/IgM)




5 (27%) 0 (0%) 13.40 (0.68-265.5) 0.08
aPL confirmed after 
3 months Positive dRVVT
3 (20%) 2 (19%) 1.08 (0.13-8.8) 0.95
Elvated cardiolipin  
(IgG/IgM)
2 (13%) 1 (5%) 1.87 (0.15-22.8) 0.62
Elevated anti-β2-
glycoprotein-I (IgM/IgG)









Lymphocytes (mm3) 1415 (1050-1740) 1575 (740-1710) — 0.81








1.04 (0.7-1.21) 0.87 (0.715-1.03) — 0,87
Serum alanine 
aminotransferase (IU/L)
33 (17.3-58.8) 38 (22.5-53.5) — 0.60
Serum aspartate 
aminotransferase (U/L)
27 (18.8-101.8) 32 (21-50) — 0.39
Serum lactate 
dehydrogenase (IU/L)





To control for possible confounding variables, sequential multivariate regression 
analyses were performed. In the multivariate analysis, the following risk factors 
were associated with thrombosis: age (p = 0.02) and D-dimer (p = 0.03). Diabetes 
and dyslipidaemia were significant predictors in univariate but not in multivariate 
analysis.
4. Discussion
The incidence of arterial and venous thrombosis associated with COVID-19 and 
laboratorial parameters has raised questions about a possible COVID-19 related 
coagulopathy. aPL has been considered as one of the mechanisms leading to a proin-
flammatory and hypercoagulable state. Hemostatic changes observed in COVID-19 
patients have been previously associated with other coronavirus, which can activate 
the coagulation system and lead to thrombotic events [30].
Our study evaluates the incidence of aPL in a cohort of patients with COVID-
19 and compares the incidence of aPL between two groups: the first group with 
thrombotic complications and the second group without thrombotic complications 
because of SARS-CoV2.
Several studies have suggested that aPL may be associated with thrombotic com-
plications in COVID-19 patients and discussed the relevance of measuring aPL titers.
In most studies, the aPL confirmation after 12 weeks is often missing. Measuring 
LAC, aCL and aβ2GPI is useful for identifying patients at risk. Current criteria 
recommend increased levels of IgG and IgM aCL and aβ2GPI to confirm APS. The 
role of IgM aPL has been discussed based on a less strong association with thrombo-
sis compared to IgG [31].
Zhang et al. has recently described the case of three patients with multiple cere-
bral infarctions that tested positive for aCL IgA and aβ2GPI IgG and IgA, without 
referring the titer or confirmation [28].
Harzallah et al. tested 56 patients for aPL and discovered that 45% had LAC 
positive, 10% aCL or aβ2GPI IgG or IgM positive. Titers of aCL or aβ2GPI were not 
reported and no association with thrombosis was mentioned [32].










OR (Cl 95%) P value
C reactive protein (mg/L) 100 (16.5-195.9) 30.6 (1.7-85.2) — 0.39
Procalcitonin (μg/L) 0.18 (0.047-0.23) 0.067 
(0.022-0.096)
— 0.18
Serum ferritin (ng/ml) 539.4 (140-792) 559.5 (70-897.5) — 0.60








Data are presented as median (25th-75th percentile) or numbers (%) as appropriate. Abbreviations:  
COVID-19: coronavirus disease 2019. aPL: antiphospholipid antibodies. Patient dRVVT screen (low 
phospholipid concentration) and confirm (high phospholipid concentration) results were normalized, i.e. 
expressed as ratios versus reference plasma results. Results are expressed as screen ratio/ confirm ratio. Cut-off 
value was 1.20 for both screen ratio and screen ratio/confirm ratio; Anticardiolipin IgG/IgM and/or anti-
β2-glycoprotein-I IgG antibodies was defined as elevated if the titer was >20 CU (99th percentile), a cut-off 
provided by the manufacturer.
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In our study, patients with thrombosis 56% showed positivity for aPL, in the 
patients without thrombosis 19% tested positive for at least one aPL during admis-
sion. We should also take into consideration that most patients were treated with 
heparins to prevent thrombotic complications.
The majority of aPL measuring studies in the break of COVID-19 lack con-
firmed positivity of aPL after three months. Positive results of LAC, aCL or aβ2GPI 
need to be confirmed after 12 week-period to confirm persistent positivity. In our 
study, we had the opportunity to retest most patients at a second time point. In the 
group with thrombotic complications, out of 8 patients who had positive LAC on a 
first occasion, 3 had persistent LAC after 12 weeks and 5 turned into negative. Out 
of the 5 patients with positive aCL during admission, 2 had persistent aCL and out 
of the 5 patients with positive aβ2GPI, 1 had persistent aβ2GPI after 12 weeks, with 
one patient being triple positive for LAC, aCL and aβ2GPI.
Transient antibodies have been described in viral diseases or drugs; therefore, 
re-testing is crucial to avoid overdiagnosis of APS patients that were not persistently 
positive [25].
Several studies have demonstrated that viral and bacterial infections, due to 
molecular mimicry between viral and bacterial products and β2GPI- derived amino 
acid sequences can induce autoantibodies such as aPL. In most cases, these infection 
induced-aPL are transient and can associate with thrombosis. It has been mentioned 
that only with the appropriate genetic background can these antibodies become 
pathogenic and induce thrombosis [33].
The most common laboratory abnormalities identified in patients with COVID-
19 include decreased albumin and lymphocyte count and elevated C-reactive 
protein (CRP), lactate dehydrogenase (LDH), erythrocyte sedimentation rate 
(ESR), aspartate transaminase (AST), alanine transaminase (ALT), and D-dimer 
[34, 35]. These abnormalities are associated with worse outcome. In our study, 
we have found that most patients with COVID-19 had hemostatic abnormalities, 
such as decreased lymphocyte count, elevated lactate dehydrogenase and elevated 
D-dimer and found significant differences between patients with thrombotic events 
and patients without thrombotic events.
Many of the laboratory abnormalities represent a balance between an acute 
phase reaction to the infection, including high CRP, high fibrinogen, high factor 
VIII, and high von Willebrand factor (VWF) and consumption of coagulation 
factors due to systemic or localized thrombosis and increase in D-dimer and 
fibrinogen [36, 37].
aPL analyses was performed during the acute phase in our study, which is mostly 
discouraged by current guidelines since, elevated levels of CRP may result in false 
positive LAC. In our cohort, we have found a significant association between CRP 
and aPL elevation and D-Dimer levels during the first testing period which could be 
interpreted as an argument in favor of these theory.
Comparing our research to previous studies that highlight the association of aPL 
and thrombosis, it remains unclear whether all these patients were prophylactically 
anticoagulated, as it was the case in our cohort.
Our study has some limitations: (1) In the analysis, for some patients, we only had 
one time-point (2) small sample size may influence statistical analysis (3) determina-
tion of aPL did not included aCL and aβ2GPI IgA.
5. Conclusion
The relevance of aPLs in patients with COVID-19 is yet to be determined. 
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mediators in COVID-19 infection can lead to thrombosis. Further studies are 
needed before to determine the role of aPL in COVID-19 patients and their relation-
ship with thrombosis. The presence of aPL should be carefully interpreted as it is 
important to evaluate the persistence of aPL positivity in patients infected with 
COVID-19.
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